What it's for (Indications)
- Treatment of hypertension (high blood pressure), heart failure, and myocardial infarction (heart attack) with left ventricular failure or left ventricular diastolic dysfunction.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage should be individualized based on the patient's blood pressure response and tolerability. This fixed-dose combination is typically administered once daily. It is not recommended as initial therapy for hypertension but rather in patients whose blood pressure is not adequately controlled on dual therapy, or who are already on stable doses of the individual components. Specific dosage strengths combine varying amounts of valsartan, amlodipine, and hydrochlorothiazide (e.g., 160/10/25 mg, 80/5/12.5 mg). |
Safety & Warnings
Common Side Effects
- Patients may rarely experience syncope (fainting), thrombocytopenia (low levels of platelets), renal (kidney) dysfunction, angioedema (swelling under skin or mucous membrane), dizziness (lightheadedness), and hypotension.
Serious Warnings
- Black Box Warning: Drugs that act directly on the renin-angiotensin system, including valsartan, can cause injury and death to the developing fetus when administered to pregnant women. Discontinue as soon as pregnancy is detected.
- This medicine should be used with caution in patients with a history of hepatic (liver) impairment, severe renal (kidney) impairment, renal artery stenosis (narrowing of renal arteries), severe cardiac insufficiency, aortic or mitral stenosis (narrowing of heart valves), and angioedema.
- Potassium levels should be monitored, especially in elderly patients.
- Avoid driving or operating machinery if the medicine affects your ability (e.
- g.
- , due to dizziness).
- Avoid consuming alcohol while taking this medicine as it may enhance hypotensive effects or other adverse reactions.
How it Works (Mechanism of Action)
Valsartan, an angiotensin II receptor blocker (ARB), selectively blocks the binding of angiotensin II to the AT1 receptor, leading to vasodilation and decreased aldosterone secretion. Amlodipine besylate, a dihydropyridine calcium channel blocker (CCB), inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing peripheral arterial vasodilation. Hydrochlorothiazide (HCTZ), a thiazide diuretic, inhibits sodium reabsorption in the distal convoluted tubules, increasing the excretion of sodium, chloride, and water. These complementary mechanisms work synergistically to lower blood pressure and manage fluid balance.